Llistar Títols

S'han trobat 24 ítems

Llistant ítems des de 0 a 24:

  1   
FormatDataTítolAutor
FormatDataTítolAutor
doc icon TDX 22 maig 2015 Bioenergetics mechanism and autophagy in breast cancer stem cells Cufí González, Sílvia
doc icon DUGiDocs 22 maig 2015 Bioenergetics mechanism and autophagy in breast cancer stem cells Cufí González, Sílvia
out url icon Recercat Bioenergetics mechanism and autophagy in breast cancer stem cells Cufí González, Sílvia
out url icon Recercat Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer Relat, Joana ; Blancafort, Adriana ; Oliveras, Glòria ; Cufí González, Sílvia ; Haro, Diego ; Marrero, Pedro F. ; Puig Miquel, Teresa
out url icon Recercat Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz, Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
out url icon Recercat Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz, Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
out url icon Recercat 5 juny 2018 Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz, Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
doc icon DUGiDocs 2011 Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models Oliveras Ferrarós, Cristina ; Vázquez Martín, Alejandro ; Queralt, Bernardo ; Adrados, Manuel ; Ortiz Duran, Maria Rosa ; Cufí González, Sílvia ; Hernández Yagüe, Xavier ; Guardeño, Raquel ; Báez, Luciana ; Martin Castillo, Begoña ; Pérez Martínez, Maria Carmen ; López Bonet, Eugeni ; Llorens Duran, Rafael de ; Bernadó, Luis ; Brunet i Vidal, Joan ; Menéndez Menéndez, Javier Abel
doc icon DUGiDocs abril 2012 Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
out url icon Recercat Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
out url icon Recercat Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
out url icon Recercat 5 juny 2018 Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts Cufí González, Sílvia ; Corominas Faja, Bruna ; Vázquez Martín, Alejandro ; Oliveras Ferrarós, Cristina ; Dorca Ribugent, Joan ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Menéndez Menéndez, Javier Abel
doc icon DUGiDocs 2011 A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines Puig i Miquel, Teresa ; Aguilar, Helena ; Cufí González, Sílvia ; Oliveras, Glòria ; Turrado, Carlos ; Ortega Gutiérrez, Sílvia ; Benhamú, Bellinda ; López Rodríguez, Maria Luz ; Urruticoechea, Ander ; Colomer, Ramon
out url icon Recercat A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines Puig i Miquel, Teresa ; Aguilar, Helena ; Cufí González, Sílvia ; Oliveras, Glòria ; Turrado, Carlos ; Ortega Gutiérrez, Sílvia ; Benhamú, Bellinda ; López Rodríguez, Maria Luz ; Urruticoechea, Ander ; Colomer, Ramon
out url icon Recercat A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines Puig i Miquel, Teresa ; Aguilar, Helena ; Cufí González, Sílvia ; Oliveras, Glòria ; Turrado, Carlos ; Ortega Gutiérrez, Sílvia ; Benhamú, Bellinda ; López Rodríguez, Maria Luz ; Urruticoechea, Ander ; Colomer, Ramon
out url icon Recercat 5 juny 2018 A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines Puig i Miquel, Teresa ; Aguilar, Helena ; Cufí González, Sílvia ; Oliveras, Glòria ; Turrado, Carlos ; Ortega Gutiérrez, Sílvia ; Benhamú, Bellinda ; López Rodríguez, Maria Luz ; Urruticoechea, Ander ; Colomer, Ramon
doc icon DUGiDocs 2014 Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment Menéndez Menéndez, Javier Abel ; Quirantes Piné, Rosa ; Rodríguez Gallego, Esther ; Cufí González, Sílvia ; Corominas Faja, Bruna ; Cuyàs, Elisabet ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Segura Carretero, Antonio ; Joven, Jorge
out url icon Recercat Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment Menéndez Menéndez, Javier Abel ; Quirantes Piné, Rosa ; Rodríguez Gallego, Esther ; Cufí González, Sílvia ; Corominas Faja, Bruna ; Cuyàs, Elisabet ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Segura Carretero, Antonio ; Joven, Jorge
out url icon Recercat Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment Menéndez Menéndez, Javier Abel ; Quirantes Piné, Rosa ; Rodríguez Gallego, Esther ; Cufí González, Sílvia ; Corominas Faja, Bruna ; Cuyàs, Elisabet ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Segura Carretero, Antonio ; Joven, Jorge
out url icon Recercat 5 juny 2018 Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment Menéndez Menéndez, Javier Abel ; Quirantes Piné, Rosa ; Rodríguez Gallego, Esther ; Cufí González, Sílvia ; Corominas Faja, Bruna ; Cuyàs, Elisabet ; Bosch Barrera, Joaquim ; Martin Castillo, Begoña ; Segura Carretero, Antonio ; Joven, Jorge
doc icon DUGiDocs 2012 Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel
out url icon Recercat Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel
out url icon Recercat Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel
out url icon Recercat 5 juny 2018 Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment Oliveras Ferrarós, Cristina ; Massaguer i Vall-llovera, Anna ; Vázquez Martín, Alejandro ; Carrion Salip, Dolors ; Queralt, Bernardo ; Cufí González, Sílvia ; Martin Castillo, Begoña ; Bosch Barrera, Joaquim ; Brunet i Vidal, Joan ; Llorens Duran, Rafael de ; Menéndez Menéndez, Javier Abel
  1   

Matèries

Autors